RadTox
Clinical cfDNA-concentration assay for treatment-response and progression monitoring in solid tumors.
- Developer
- DiaCarta
- Intended use
- Monitoring
- Cancer scope
- Solid tumors
- Specimen
- Plasma
- Molecular modality
- DNA
- Current version
- Current RadTox direct cfDNA-concentration monitoring configuration based on QuantiDNA technology (2026-09)
- Evidence context
- 0 structured studies · 0 indexed performance results · 1 sources
Why can reported performance numbers differ? MDI keeps each result attached to its study, population, stage or stratum, test version and source rather than treating performance as a fixed property of the test.